Lowest-Rated StocksLowest-RatedNYSE:NVRO Nevro (NVRO) Stock Price, News & Analysis → Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press) (Ad) Free NVRO Stock Alerts $9.27 -0.18 (-1.90%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$9.15▼$9.5550-Day Range$9.17▼$13.5952-Week Range$8.93▼$26.63Volume329,866 shsAverage Volume512,362 shsMarket Capitalization$340.48 millionP/E RatioN/ADividend YieldN/APrice Target$19.46 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Nevro alerts: Email Address Nevro MarketRank™ Stock AnalysisAnalyst RatingReduce1.92 Rating ScoreUpside/Downside109.9% Upside$19.46 Price TargetShort InterestBearish10.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.12) to ($2.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.96 out of 5 starsMedical Sector588th out of 905 stocksSurgical & Medical Instruments Industry70th out of 97 stocks 4.0 Analyst's Opinion Consensus RatingNevro has received a consensus rating of Reduce. The company's average rating score is 1.92, and is based on 1 buy rating, 10 hold ratings, and 2 sell ratings.Amount of Analyst CoverageNevro has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nevro's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.02% of the outstanding shares of Nevro have been sold short.Short Interest Ratio / Days to CoverNevro has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Nevro has recently decreased by 4.91%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNevro does not currently pay a dividend.Dividend GrowthNevro does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVRO. Previous Next 2.7 News and Social Media Coverage News SentimentNevro has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Nevro this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for NVRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nevro insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Nevro is held by insiders.Percentage Held by Institutions95.52% of the stock of Nevro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nevro's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nevro are expected to decrease in the coming year, from ($2.12) to ($2.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nevro is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nevro is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNevro has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nevro's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanySecret energy grid to power millions of homesThis high-security, secret U.S. facility has 2,100 engineers, machinists, and technicians building a new type of energy system the world has never seen before.Click here to get all the details. About Nevro Stock (NYSE:NVRO)Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Read More NVRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVRO Stock News HeadlinesJune 1, 2024 | americanbankingnews.comNevro Corp. (NYSE:NVRO) Given Consensus Rating of "Reduce" by AnalystsMay 25, 2024 | finanznachrichten.deNevro Corp.: Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08May 24, 2024 | prnewswire.comNevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08May 23, 2024 | msn.comCitigroup Downgrades Nevro (NVRO)May 13, 2024 | markets.businessinsider.comBank of America Securities Keeps Their Sell Rating on Nevro Corp (NVRO)May 13, 2024 | markets.businessinsider.comTruist Financial Remains a Hold on Nevro Corp (NVRO)May 10, 2024 | markets.businessinsider.comNevro Corp: Cautious Outlook Amidst Restrained Growth and Strategic EffortsMay 10, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their Nevro Corp. (NYSE:NVRO) Price Target To US$15.30May 9, 2024 | prnewswire.comNevro to Present at BofA Securities 2024 Healthcare ConferenceMay 8, 2024 | markets.businessinsider.comAssessing Nevro: Insights From 9 Financial AnalystsMay 8, 2024 | markets.businessinsider.comHold Rating on Nevro Corp Amidst Strong Q1 Performance and Conservative OutlookMay 8, 2024 | finance.yahoo.comNevro Corp. (NYSE:NVRO) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comNevro Corp (NVRO) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of Financial ...May 7, 2024 | prnewswire.comNevro Reports First-Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comNevro earnings preview: what Wall Street is expectingApril 17, 2024 | finance.yahoo.comNevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024April 17, 2024 | prnewswire.comNevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024April 3, 2024 | benzinga.comWhere Nevro Stands With AnalystsMarch 25, 2024 | finanznachrichten.deEnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology CommercializationMarch 11, 2024 | finance.yahoo.comNVRO Mar 2024 20.000 putFebruary 28, 2024 | prnewswire.comNevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral ScrewFebruary 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)February 26, 2024 | markets.businessinsider.comNevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market UncertaintyFebruary 23, 2024 | realmoney.thestreet.comNevro just downgraded at Oppenheimer, here's whyFebruary 22, 2024 | finanznachrichten.deNevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial ResultsSee More Headlines Receive NVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/08/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:NVRO CUSIPN/A CIK1444380 Webwww.nevro.com Phone(650) 251-0005FaxN/AEmployees1,215Year FoundedN/APrice Target and Rating Average Stock Price Target$19.46 High Stock Price Target$40.00 Low Stock Price Target$9.00 Potential Upside/Downside+109.9%Consensus RatingReduce Rating Score (0-4)1.92 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,210,000.00 Net Margins-19.17% Pretax Margin-20.47% Return on Equity-27.48% Return on Assets-13.40% Debt Debt-to-Equity Ratio0.77 Current Ratio7.38 Quick Ratio5.57 Sales & Book Value Annual Sales$430.75 million Price / Sales0.79 Cash FlowN/A Price / Cash FlowN/A Book Value$8.10 per share Price / Book1.14Miscellaneous Outstanding Shares36,729,000Free Float35,554,000Market Cap$340.48 million OptionableOptionable Beta0.95 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Kevin R. Thornal (Age 50)President, CEO & Director Comp: $1.37MMr. Roderick H. MacLeod (Age 57)Senior VP & CFO Comp: $653.1kMr. Kashif Rashid (Age 50)Senior VP of Corporate Development & Chief Legal Officer Comp: $629.62kMr. Greg Siller (Age 43)Senior VP & Chief Commercial Officer Comp: $419.9kMr. Richard B. Carter (Age 53)Chief Accounting Officer Mr. Christofer Christoforou (Age 54)Senior Vice President of Technical Operations Comp: $367.4kGeeta KavetiVP and Chief Compliance & Privacy OfficerMeredith VornholtVice President of Global MarketingMs. Shana D. Ross M.B.A. (Age 51)Senior VP & Chief Human Resources Officer Dr. David Caraway M.D. (Age 67)Ph.D., Senior VP & Chief Medical Officer More ExecutivesKey CompetitorsAlphatecNASDAQ:ATECAtriCureNASDAQ:ATRCMiMedx GroupNASDAQ:MDXGArtivionNYSE:AORTPerspective TherapeuticsNYSE:CATXView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemSold 5,051 shares on 5/16/2024Ownership: 0.090%Bellevue Group AGSold 62,089 shares on 5/15/2024Ownership: 0.368%Lazard Asset Management LLCSold 11,596 shares on 5/15/2024Ownership: 0.365%Price T Rowe Associates Inc. MDBought 7,004 shares on 5/15/2024Ownership: 0.123%CANADA LIFE ASSURANCE CoSold 6,686 shares on 5/14/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions NVRO Stock Analysis - Frequently Asked Questions Should I buy or sell Nevro stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 2 sell ratings, 10 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" NVRO shares. View NVRO analyst ratings or view top-rated stocks. What is Nevro's stock price target for 2024? 13 analysts have issued 12 month target prices for Nevro's stock. Their NVRO share price targets range from $9.00 to $40.00. On average, they anticipate the company's stock price to reach $19.46 in the next twelve months. This suggests a possible upside of 109.9% from the stock's current price. View analysts price targets for NVRO or view top-rated stocks among Wall Street analysts. How have NVRO shares performed in 2024? Nevro's stock was trading at $21.52 at the beginning of the year. Since then, NVRO shares have decreased by 56.9% and is now trading at $9.27. View the best growth stocks for 2024 here. When is Nevro's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our NVRO earnings forecast. How were Nevro's earnings last quarter? Nevro Corp. (NYSE:NVRO) announced its quarterly earnings results on Tuesday, May, 7th. The medical equipment provider reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($1.02) by $0.32. The medical equipment provider earned $101.90 million during the quarter, compared to analyst estimates of $97.90 million. Nevro had a negative net margin of 19.17% and a negative trailing twelve-month return on equity of 27.48%. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.98) EPS. What ETFs hold Nevro's stock? ETFs with the largest weight of Nevro (NYSE:NVRO) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), Fidelity Digital Health ETF (FDHT) and iShares Neuroscience and Healthcare ETF (IBRN).iShares U.S. Medical Devices ETF (IHI). What guidance has Nevro issued on next quarter's earnings? Nevro updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $435.0 million-$445.0 million, compared to the consensus revenue estimate of $441.0 million. What is D. Keith Grossman's approval rating as Nevro's CEO? 9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees. What other stocks do shareholders of Nevro own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG). Who are Nevro's major shareholders? Nevro's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.65%), Principal Financial Group Inc. (1.94%), Bellevue Group AG (0.37%), Lazard Asset Management LLC (0.37%), Assenagon Asset Management S.A. (0.34%) and Susquehanna Fundamental Investments LLC (0.27%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane and Shawn Mccormick. View institutional ownership trends. How do I buy shares of Nevro? Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NVRO) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nevro Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nevro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.